CN1377424A - 由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长 - Google Patents

由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长 Download PDF

Info

Publication number
CN1377424A
CN1377424A CN00813712A CN00813712A CN1377424A CN 1377424 A CN1377424 A CN 1377424A CN 00813712 A CN00813712 A CN 00813712A CN 00813712 A CN00813712 A CN 00813712A CN 1377424 A CN1377424 A CN 1377424A
Authority
CN
China
Prior art keywords
cell
cells
gene
senescent
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00813712A
Other languages
English (en)
Chinese (zh)
Inventor
M·维斯特
R·L·兰扎
J·希柏利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Advanced Cell Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cell Technology Inc filed Critical Advanced Cell Technology Inc
Publication of CN1377424A publication Critical patent/CN1377424A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
CN00813712A 1999-09-07 2000-09-06 由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长 Pending CN1377424A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15234099P 1999-09-07 1999-09-07
US60/152,340 1999-09-07
US17948600P 2000-02-01 2000-02-01
US60/179,486 2000-02-01
US52702600A 2000-03-16 2000-03-16
US09/527,026 2000-03-16
US52087900A 2000-04-05 2000-04-05
US09/520,879 2000-04-05

Publications (1)

Publication Number Publication Date
CN1377424A true CN1377424A (zh) 2002-10-30

Family

ID=27496015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00813712A Pending CN1377424A (zh) 1999-09-07 2000-09-06 由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长

Country Status (10)

Country Link
EP (1) EP1214443A4 (https=)
JP (1) JP2003508079A (https=)
CN (1) CN1377424A (https=)
AU (1) AU7350800A (https=)
BR (1) BR0013844A (https=)
CA (1) CA2383790C (https=)
IL (2) IL148457A0 (https=)
MX (1) MXPA02002443A (https=)
NZ (1) NZ531844A (https=)
WO (1) WO2001018236A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562376A (zh) * 2011-04-08 2014-02-05 国家医疗保健研究所 复壮细胞的方法
CN112280739A (zh) * 2008-05-06 2021-01-29 安斯泰来再生医药协会 用于制备衍生自多能干细胞的去核类红细胞的方法
CN112654244A (zh) * 2018-09-06 2021-04-13 德克萨斯大学系统董事会 端粒酶全酶复合体及其使用方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018193A1 (en) * 1999-09-07 2001-03-15 Advanced Cell Technology, Inc. Method for generating immune-compatible cells and tissues using nuclear transfer techniques
US7947457B2 (en) 2007-01-08 2011-05-24 The Invention Science Fund I, Llc Systems for genome selection
US7709245B2 (en) 2007-01-08 2010-05-04 The Invention Science Fund I, Llc Systems for genome selection
US8003371B2 (en) 2007-01-08 2011-08-23 The Invention Science Fund I, Llc Systems for genome selection
US7718418B2 (en) 2007-01-08 2010-05-18 The Invention Science Fund I, Llc Systems for genome selection
US7709244B2 (en) 2007-01-08 2010-05-04 The Invention Science Fund I, Llc Systems for genome selection
US8012740B2 (en) 2007-01-08 2011-09-06 The Invention Science Fund I, Llc Systems for genome selection
US7947455B2 (en) 2007-01-08 2011-05-24 The Invention Science Fund I, Llc System for genome selection
US7985578B2 (en) 2007-01-08 2011-07-26 The Invention Science Fund I, Llc Systems for genome selection
US8521440B2 (en) 2007-01-08 2013-08-27 The Invention Science Fund I, Llc Systems for genome selection
US7648823B2 (en) 2007-01-08 2010-01-19 Searete Llc Systems for genome selection
US7713728B2 (en) 2007-01-08 2010-05-11 The Invention Sciencefund I, Llc Systems for genome selection
JP5888852B2 (ja) * 2010-12-08 2016-03-22 学校法人近畿大学 免疫不全動物を用いた細胞の製法
EP3782628B1 (en) * 2013-03-15 2024-08-07 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejuvenating human cells
SG10201907918VA (en) 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
EP4525895A1 (en) * 2022-05-17 2025-03-26 National University of Singapore Chimeric ovarian follicle-based therapy to treat female infertility

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5648215A (en) * 1992-05-13 1997-07-15 Board Of Regents, The University Of Texas System Telomerase diagnostic methods
US5945577A (en) * 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
AU745334B2 (en) * 1997-03-06 2002-03-21 Advanced Cell Technology, Inc. Method of cloning animals
GB9809178D0 (en) * 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
AU782286B2 (en) * 1999-06-30 2005-07-14 Advanced Cell Technology, Inc. Cytoplasmic transfer to de-differentiate recipient cells
WO2001018193A1 (en) * 1999-09-07 2001-03-15 Advanced Cell Technology, Inc. Method for generating immune-compatible cells and tissues using nuclear transfer techniques

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112280739A (zh) * 2008-05-06 2021-01-29 安斯泰来再生医药协会 用于制备衍生自多能干细胞的去核类红细胞的方法
CN103562376A (zh) * 2011-04-08 2014-02-05 国家医疗保健研究所 复壮细胞的方法
CN103562376B (zh) * 2011-04-08 2017-12-29 国家医疗保健研究所 复壮细胞的方法
CN112654244A (zh) * 2018-09-06 2021-04-13 德克萨斯大学系统董事会 端粒酶全酶复合体及其使用方法

Also Published As

Publication number Publication date
WO2001018236A1 (en) 2001-03-15
NZ531844A (en) 2005-08-26
IL148457A (en) 2013-01-31
JP2003508079A (ja) 2003-03-04
EP1214443A4 (en) 2003-08-27
CA2383790A1 (en) 2001-03-15
AU7350800A (en) 2001-04-10
CA2383790C (en) 2016-11-22
MXPA02002443A (es) 2004-07-16
IL148457A0 (en) 2002-09-12
BR0013844A (pt) 2002-05-14
EP1214443A1 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
CN1377424A (zh) 由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长
Tu et al. Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos
US20040180430A1 (en) Methods of restoring telomere length and extending cell lifespan using nuclear transfer
JP3571337B2 (ja) 遺伝子標的現象による同型遺伝子接合
Vodička et al. The miniature pig as an animal model in biomedical research
CN100335625C (zh) 来自有蹄动物胚胎的培养内细胞团细胞系
RU2015101740A (ru) Генетически модифицированные животные и способы их получения
WO2001018236A9 (en) Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
JP2019502400A (ja) キメラ胚補助臓器作製用の組成物及び方法
CN1212009A (zh) 有蹄动物胚胎干样细胞、制法及用该细胞产生转基因的有蹄动物的方法
Ratner et al. Practical approaches for knock-out gene editing in pigs
Li et al. Passage number affects the pluripotency of mouse embryonic stem cells as judged by tetraploid embryo aggregation
US20020046410A1 (en) Method for generating immune-compatible cells and tissues using nuclear transfer techniques
CN110283847A (zh) 一种同时定点整合fad3和fabp4基因的载体及重组细胞
Oback et al. Chimaeras, complementation, and controlling the male germline
CN1377225A (zh) 使用来自分化细胞的供体细胞或细胞核克隆猪以及多能猪的生成
JP2023518379A (ja) 標的配列の切断のための最適化された方法
Suvá et al. Use of an exogenous DNA-free system to generate MSTN-KO calves by CRISPR/Cas9 and SCNT
Tahajjodi et al. Cumulus cells conditioned medium facilitates germ cell differentiation from human embryonic stem cells: An experimental study
KR102738812B1 (ko) 돼지 GGTA1, CMAH, β4GalNT2 및 CD40 유전자가 결손된 이종장기이식을 위한 형질전환 복제돼지 및 이의 제조방법
CN1650003A (zh) 选择用于哺乳动物种中核转移的细胞系的方法
US20120196769A1 (en) Methods of repairing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
Suvá et al. First sex modification case in equine cloning
KR20220098613A (ko) 유전자 변형된 세포 선별(sorting out) 위한 방법 및 물질
Reyes et al. Efficient selection of Gal-knockout pig cells for somatic cell nuclear transfer

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication